EP6 Standard Glucocorticoid Drug Raw Fluocinonide Powder For Sale
What is Fluocinonide?
Fluocinonide is a potent glucocorticoid used topically as an anti-inflammatory agent for the treatment of skin disorders such as eczema and seborrhoeic dermatitis. It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort.
Fluocinonide Basic Information
Synonyms:1,4-Pregnadien-6-Alpha, 9-Alpha-Difluoro-11-Beta, 16-Alpha, 17,21-Tetrol-3,20-Dione 16,17-Acetonide 21-Acetate;Fluocinolone Acetonide 21-Acetate;Fluocinomide;Fluocinonide Acetonide 21-Acetate;Flucinar;Fluocinolide, Fluonex, Lidex, Lidex-E, Lonide, Lyderm, and Vanos
CAS: 356-12-7
MF:C26H32F2O7
MW:494.52
EINECS:206-597-6
Appearance: White or white crystalline powder
Assay:97-103%
Melting point:309C
Uses : Glucocorticoid; anti-inflammatory.
Packing:1kg/tin
Fluocinonide Certificate of Analysis
Product name |
Fluocinonide |
CAS No. |
356-12-7 |
Outer Packing |
1kg |
Production date |
11th Jan 2018 |
Shelf life |
10th Jan 2021 |
Standard adopted |
EP6 |
Items of analysis |
Specification |
Results |
Appearance |
White or white crystalline powder |
White crystalline powder |
Identification |
(1) UV (2) IR |
Conforms |
Specific Rotation |
+81° ~ +88° |
+86.7° |
Single impurity |
≤1.0% |
0.39% |
Total impurity |
≤2% |
1.64% |
Dry weight loss |
≤1.0% |
0.36% |
Content |
97-103% |
98.6% |
Conclusion |
Qualified |
Fluocinonide Medical Uses
This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Fluocinonide reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a strong corticosteroid.
Fluocinonide Use Notes
Fluocinonide ranks as a “high-potency” (second-highest rank) topical corticosteroid. Minimal amounts should be used for a minimal length of time to avoid the occurrence of adverse effects.
Fluocinonide should not be used if infection is present. It should not be applied to the eyes or to sensitive areas such as the genitals or anus.
A common potential adverse effect is skin atrophy (thinning of the skin). Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis (HPA) suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.